Avalo CMO exercises options and sells 3,000 shares

Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock.

Rhea-AI Filing Summary

Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On May 15, 2026, she exercised stock options to acquire 3,000 shares of common stock at $12.65 per share, then sold 3,000 shares in an open-market transaction at $18.76 per share.

After these transactions, she directly holds 3,622 shares of common stock and 128,625 stock options. The filing states the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,000 shares ($18K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 3,000 shs ($56K)

Approx. gross sale proceeds $56K

Approx. exercise cost $38K

Approx. pre-tax spread $18K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	$0.00
Exercise	Common Stock	3,000	$12.65	$38K
Sale	Common Stock	3,000	$18.76	$56K

Holdings After Transaction: Stock Option (Right to Buy) — 128,625 contracts (Direct); Common Stock — 3,622 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 3,000 shares Sale price: $18.76 per share Option exercise price: $12.65 per share +3 more

6 metrics

Shares sold 3,000 shares Open-market sale of common stock on May 15, 2026 at $18.76

Sale price $18.76 per share Price for 3,000 common shares sold on May 15, 2026

Option exercise price $12.65 per share Exercise price for 3,000 stock option shares converted to common

Common shares after transaction 3,622 shares Direct common stock holdings following the reported transactions

Remaining stock options 128,625 options Stock options outstanding after 3,000-share exercise; expire July 15, 2034

Rule 10b5-1 plan adoption date November 13, 2025 Date the trading plan governing these transactions was adopted

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying common stock"

open-market sale financial

"transaction_action: "open-market sale" for 3,000 common shares at $18.76"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for 3,000 underlying shares"

expiration date financial

"stock option shows an expiration date of 2034-07-15 for remaining options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for Mittie Doyle?

Avalo Therapeutics reported that Chief Medical Officer Mittie Doyle exercised options for 3,000 shares and sold 3,000 shares of common stock on May 15, 2026. This reflects an exercise-and-sell pattern rather than a simple open-market purchase or sale.

At what prices did Mittie Doyle exercise and sell Avalo Therapeutics (AVTX) shares?

Mittie Doyle exercised stock options at $12.65 per share and sold 3,000 Avalo Therapeutics common shares at $18.76 per share. The option exercise converted derivative awards into stock, followed by an open-market sale at the higher trading price.

How many Avalo Therapeutics (AVTX) shares does Mittie Doyle hold after the Form 4 transactions?

Following the reported transactions, Mittie Doyle directly holds 3,622 shares of Avalo Therapeutics common stock. She also retains 128,625 stock options, representing additional potential future equity exposure if those options are exercised later.

Were Mittie Doyle’s Avalo Therapeutics (AVTX) trades made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such pre-arranged plans automate trading, reducing the significance of trade timing as an indicator of insider sentiment.

What type of options did Mittie Doyle exercise in the Avalo Therapeutics (AVTX) Form 4?

She exercised a stock option described as a “Stock Option (Right to Buy)” covering 3,000 underlying common shares at a $12.65 exercise price. After this exercise, 128,625 option shares remain outstanding with an expiration date of July 15, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		M(1)		3,000	A	$12.65	6,622	D
Common Stock	05/15/2026		S(1)		3,000	D	$18.76	3,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.65	05/15/2026		M(1)			3,000	(2)	07/15/2034	Common Stock	3,000	$0	128,625	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)